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Abstract
Enteric protozoa usually cause severe morbidity and mortality in humans. 
Protozoal infections contribute to the high burden of infectious diseases. Despite 
recent advances in the epidemiology, diagnostic tool, molecular biology, and 
treatment of protozoan illnesses, gaps in knowledge still exist; hence, protozoal 
infections require further research. We are describing here some important enteric 
protozoal infections along with the immune dysfunction produced by them. Genus- 
1. Entamoeba; 2. Giardia; 3. Cryptosporidium; 4. Cyclospora; 5. Cystoisospora; 6. 
Dientamoeba; 7. Blastocystis; 8. Balantidium.
Keywords: parasite, protozoa, trophozoites, cysts, molecular characterization, 
laboratory diagnosis, treatment, vaccine
1. Introduction
Parasites are living organisms, which live in or upon another organism and 
derive nutrients directly from it, without giving any benefit to host. There are three 
main classes of parasites: protozoa, helminthes, and ectoparasites.
In the current chapter, we are going to discuss about pathogenic proto-
zoan parasites responsible for intestinal infections and the immune system 
disturbance produced by them. Protozoa are unicellular organisms classified 
as eukaryotes. Protozoa responsible for intestinal infections are Entamoeba, 
Giardia, Cryptosporidium, Cyclospora, Cystoisospora, Dientamoeba, Blastocystis, 
and Balantidium. These enteric protozoa are associated with diarrheal illnesses in 
humans, with some causing severe debilitating illnesses, especially in immunosup-
pressed populations [1].
Enteric protozoa have been given much attention in developing countries, 
because of their poor sanitary conditions and the unavailability of effective water 
treatment, which provide a suitable environment for their transmission [2–4]. In 
more industrialized settings, less focus has been placed on the impact of protozoal 
infection, presumably because of better health standards. As a result of underdiag-
nosis and lack of monitoring programs, reliable data are not available for the esti-
mation of the protozoal disease burden in developed settings [5]. The major focus in 
developed countries is on bacterial and viral infections; hence, in operational sur-
veillance systems, only a few or no parasitic protozoa are included [6, 7]. However, 
evidence suggests that some protozoa, like Entamoeba spp., Cryptosporidium, and 
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Giardia, are isolated frequently from diarrheal patients in developing countries 
(8). Others, such as Blastocystis spp. and Dientamoeba fragilis, are isolated mainly 
in developed countries [8, 9]. Despite the lower prevalence of parasitic diseases in 
developed countries, they may result in a greater economic burden on the country.
Many protozoal diseases appearing and reappearing in developed countries 
presented as a public health problem in developing countries long before. The 
factors that influence the emergence and reemergence of the protozoal disease 
are similar to other diseases like change in the parasite or host that favor increased 
transmission, environment, and demographic change that favor increased human-
parasite contact and increased the recognition of previously existing problem due to 
availability of more advanced diagnostic techniques.
There is lack of sensitive diagnostic techniques to detect parasite in clinical 
specimens, and hence, the estimation of parasite prevalence is difficult, and the 
carrier stages and subclinical infections of parasites are often not diagnosed [10]. 
So the development of technologies that can simultaneously detect several protozoa 
in stool is the current need of the hour [11, 12]. For the sensitive, accurate, and 
simultaneous detection of protozoan parasites, the molecular techniques are the 
most promising methods in comparison to conventional staining and microscopy 
methods [12]. Unfortunately, the molecular methods are not used routinely for the 
detection of parasitic protozoa because these are costly and labor-intensive [13]. 
Much effort must now be placed in the development of inexpensive molecular tools 
for routine laboratory applications.
2. Enteric protozoal infections
The enteric protozoa that are considered as a major public health problem are 
Entamoeba histolytica, Giardia intestinalis, Cryptosporidium spp., Dientamoeba fragi-
lis, Cyclospora cayetanensis, Blastocystis spp., Cystoisospora belli, and Balantidium coli.
2.1 Entamoeba species
2.1.1 Introduction
Genus Entamoeba is divided into six species that have been described in 
humans, including Entamoeba histolytica, Entamoeba dispar, Entamoeba moshkovskii, 
Entamoeba polecki, Entamoeba coli, and Entamoeba hartmanni. Among these,  
E. histolytica is the only pathogenic species [10, 14, 15]. Infection of E. histolytica is 
mainly seen in immigrants from or travelers to areas of endemicity, male having sex 
with male (MSM), HIV-infected patients, and institutionalized populations [16]. 
Millions of people are infected with E. histolytica, and more than 55,000 people die 
each year globally due to amoebic colitis, a leading cause of diarrhea [17].
2.1.2 Epidemiology
Globally, the highest burden of amebiasis is seen in tropical and subtropical areas 
of developing countries because of their improper hygiene and water sanitation. It was 
estimated that E. histolytica affect millions of people and responsible for the death of 
more than 50,000 people each year globally [1]. Amebiasis is also seen in the devel-
oped world, mostly in returning travelers or immigrants from endemic countries [18].
It has been noticed that the prevalence of E. histolytica/dispar has increased to 
36.6% in developed world from 2000 to 2015 [19] in comparison to 1986 in which it 
was 20% as per Boston report [20].
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2.1.3 Pathogenesis
Transmission—Amebiasis is acquired by the ingestion of cyst via the fecal-oral 
route, but now it is found that fecal contact can occur during sexual contact also 
(MSM–male having sex with men).
Life cycle—Following ingestion cyst converts into trophozoites known as 
invasive form of Entamoeba histolytica. In asymptomatic individuals, cysts and 
trophozoites pass into the stool without invading intestinal mucosa, whereas in 
a few cases, it invade intestinal mucosa and lead to invasive manifestations of 
Entamoeba histolytica like dysentery, amoebic colitis, and ameboma. After invad-
ing intestinal mucosa, trophozoites can travel to other organ via bloodstream and 
manifest as brain abscess and liver abscess [21, 22]. Males are more commonly 
affected from this invasive disease than females (Figure 1).
Pathophysiology—The virulence factors of E. histolytica are its enzymes and 
proteases that help in the invasion of the epithelial cells, penetrating the intes-
tinal mucosa and degradation of the extracellular matrix proteins [23, 24]. More 
recently it is thought that some individuals are genetically resistant to infec-
tion, while malnourished children are more susceptible, and a polymorphism 
in the leptin receptor is found to be associated with increased susceptibility to 
 amebiasis [24, 25].
2.1.4 Immune dysfunction
In some cases, E. histolytica colonizes the colon by high-affinity binding to 
MUC2 mucin without producing any symptoms, whereas in some it causes an 
Figure 1. 
Life cycle of Entamoeba histolytica. Courtesy: Ref. [110], Fig. 218–1.
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aggressive inflammatory response upon invasion of the colonic mucosa. The 
parasite has cysteine protease that cleaves C-terminus of MUC2 that dissolves the 
mucus layer followed by binding of E. histolytica to the mucosal epithelium. As a 
result, the host mounts a pro-inflammatory response that causes tissue damage 
and participates in disease pathogenesis. E. histolytica escapes the host immune 
system by mechanisms that are not completely understood. The parasite can destroy 
effector immune cells by inducing neutrophil apoptosis and suppressing respiratory 
burst. It also suppresses the production of nitric oxide (NO) from macrophages. 
Following the adherence of E. histolytica to the host cells, multiple cytotoxic effects 
occur that can promote cell death through phagocytosis and apoptosis, which might 
play critical roles in immune evasion [26].
2.1.5 Diagnosis
For the early diagnosis of invasive and extraintestinal amebiasis, a high level of 
clinical suspicion is necessary [27].
Morphological similarities of the pathogenic species E. histolytica to the non-
pathogenic species E. dispar and E. moshkovskii make the diagnosis difficult. Hence, 
microscopy is usually considered insufficient for the differentiation of these species 
[28]. In microscopic techniques, trichrome-stained smears and wet mount prepara-
tions of stool specimens are used in routine for the identification of Entamoeba spp. 
[29]. Other methods for Entamoeba identification include culture, antigen-based, 
and molecular tests.
In culture methods, polyxenic culture media like Balamuth’s medium and axenic 
culture media like diamond’s medium are used. A new axenic culture medium 
CLUPS for the growth of E. histolytica was also there which is superior to previously 
used PEHPS media [30]. However, cultivation is more sensitive than microscopy, 
but these methods are time-consuming, not cost-effective, and hence not routinely 
utilized by most diagnostic laboratories. Cultivation can effectively distinguish 
between E. dispar and E. histolytica [31].
Enzyme immunoassay (EI) kits are commercially available that detect E. 
histolytica or differentiate between E. histolytica and E. dispar by detecting 170 kDa 
of lectin antigen.
A rapid immunochromatographic testing (ICT) assay is available that detects 
antigens of E. histolytica and E. dispar (29 kDa surface antigen) in stool; however, 
this assay cannot differentiate between E. histolytica and E. dispar [29]. This assay 
also detects antigens of Giardia (alpha 1 Giardia antigen) and Cryptosporidium 
(protein disulfide isomerase antigen).
For the detection of E. histolytica antibodies in human serum serological meth-
ods such as latex agglutination, indirect hemagglutination (IHA), immunofluores-
cence assay (IFA), and enzyme-linked immunosorbent assay (ELISA) are highly 
sensitive [10, 32]. However, in endemic areas serology is of limited use because of 
the difficulty in distinguishing between past and present infections [10].
Molecular assays (like PCR) for the detection and differentiation of Entamoeba 
species are now considered as the gold standard for diagnosis of Entamoeba [28, 33]. 
When species differentiation is difficult or not possible than E. histolytica/E. dispar 
complex should be reported.
BioFire FilmArray system is the fully automated PCR system which can detect 
bacterial, viral, parasitic (E. histolytica, Giardia, Cyclospora, Cryptosporidium) diar-
rheal pathogen by using gastrointestinal panel [34].
For the diagnosis of invasive disease, a combination of microscopy, culture, and 
serology should be used with a PCR assay or with abdominal imaging (when PCR is 
unavailable) [32].
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2.1.6 Treatment
In asymptomatic carriers of E. histolytica, luminal agents should be used to mini-
mize the spread of disease. The treatment of choice is different for intestinal and 
invasive disease; hence, diagnosis is important before treatment. Metronidazole, a 
tissue amoebicide, is highly effective and used for invasive amoebic disease along 
with a luminal agent for the elimination of intestinal colonization [35]. Other agents 
like tinidazole and ornidazole can also be used for the treatment of invasive disease. 
For the treatment of intestinal and asymptomatic infections, the luminal agents 
paromomycin, iodoquinol, and diloxanide furoate are strictly recommended, as 
they are effective in eliminating cysts from the intestinal tract [36].
Regimen: asymptomatic carriage—luminal agent, Idoquinolone 650 mg tid for 
20 days or Paromomycine 500 mg tid for 10 days.
Acute colitis—Metronidazole 750 PO or IV for 5–10 days or tinidazole 2 g/d PO 
for 3 days Plus luminal agent as above.
Amebic liver abscess—Metronidazole 750 PO or IV for 5–10 days or tinidazole 
2 g/d PO once or ornidazole 2 g/d PO once Plus luminal agent as above.
2.1.7 Prevention and control
By avoiding the consumption of contaminated food and water and by treating 
the asymptomatic person, the infection can be prevented.
Certain vaccines against E. histolytica are under trial like colonization block-
ing vaccine targeting SREHP, 170 kDa subunit of lectin antigen, and 29 kDa 
cysteine-rich protein. Till now no vaccines against E. histolytica are licensed for 
human use [37, 38].
2.2 Giardia intestinalis
2.2.1 Introduction
Giardia intestinalis also known as Giardia duodenalis and Giardia lamblia is 
a common cause of parasitic diarrhea. It belongs to the flagellate group and first 
discovered by Leeuwenhoek in 1681 in his own stool.
2.2.2 Epidemiology
Giardia lamblia is distributed worldwide and reported from both temperate and 
tropical countries of the world. The prevalence of Giardia in low- and high-income 
countries is 4–43% and 1–7%, respectively [39, 40]. It was reported that Giardia 
affect approximately 2% of adults and 8% of children in developed countries [41].
Because of the increasing burden of illness from Cryptosporidium spp. and 
Giardia and their ability to impair development and socioeconomic improvements, 
they were included in the WHO Neglected Diseases initiative in 2004 [14].
2.2.3 Pathogenesis
Transmission—The most important mode of infection is fecal-oral route, but 
various studies have also found evidence of zoonotic transmission [42]. Giardiasis 
presents mainly as acute or chronic diarrhea associated with abdominal pain, 
nausea, malabsorption, and weight loss. Giardia infection can lead to growth 
retardation in malnourished children [43] and zinc deficiency in school-aged 
children [44]. Giardia infection is also common in dogs and cats [45]. They are 
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also a potential source of human infection that may be acquired through handling, 
sleeping together, licking, and kissing, as the zoonotic genotypes of Giardia were 
isolated from cats and dogs [46]. Giardiasis is also associated with waterborne 
disease outbreaks and is related to travel-associated diarrhea [47].
Life cycle—Cyst is the infective form of Giardia and ingestion of as low as 10 cysts 
can initiate infection. After ingestion excystation occurs in the small intestine, and its 
cyst converts into trophozoites. These trophozoites do not disseminate hematogenously 
and remain in the small bowel. It can either attach to the intestinal epithelium via 
suckling disc or remain free in the intestinal lumen. Trophozoites convert into cyst 
form, and both trophozoite and cysts are excreted in feces, but only the cysts are capable 
of surviving in the outside environment and disease transmission (Figure 2).
Pathophysiology—After attachment to the intestinal epithelium, it feed on the 
mucus secretions and lead to apoptosis of enterocyte; epithelial detection tests are 
used for screening and are more sensitive than routine microscopic examination. 
Loss of brush border is also seen.
All of these consequences manifest as lactose intolerance and malabsorption 
syndrome.
Figure 2. 
Life cycle of Giardia. Courtesy: Ref. [111], Fig. 224–1.
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2.2.4 Immune dysfunction
Both B cell-mediated antibody production and T cell-mediated immune 
responses play an in important role in protection against Giardiasis. Humans with 
immunodeficiency disorders like common variable immunodeficiency (CVID) 
and impaired IgA function have an increased risk of developing chronic Giardia 
infections. People living in endemic areas are less prone to infection or reinfection, 
indicating that acquired immunity exists.
According to a study, cellular immune response to Giardia can be understood by 
murine models. The mice model shows that in the absence of CD4+ T cells, poor 
control or chronic infection to giardia occurs, indicating that these cells are crucial 
for the murine defense against G. lamblia. Cytokines like tumor necrosis factor 
alpha (TNF-α) and gamma interferon (IFN-γ) has been shown to be important for 
determining the parasite load and the duration of an infection.
Cytokines that are secreted by CD4+ T cells were found in the mice infected with 
Giardia, indicating that a range of TH responses may contribute to the protection 
against Giardia.
In another study, it was found that following infection of G. lamblia, there is an 
upregulation of peroxisome proliferator-activated receptor alpha and interleukin-17A 
(IL-17A) [48]. IL-17A was also found to be upregulated in another mouse study also, 
where IL-17A and its receptor were important for defense against the parasite [49]. 
Hence, on the basis of these studies, IL-17A may be linked to protection against Giardia.
Some human studies for Giardia-specific immune responses were also there. In 
one study, IFN-γ was secreted, and cells were proliferating after the stimulation of 
CD4+ T cells with Giardia trophozoites, suggesting that Giardia-specific prolifera-
tion of CD4+ T cells exists in humans as well [50].
The relative importance of the cytokines IL-17A, IFN-γ, TNF-α, IL-4, 
and IL-10 in the T cell response to Giardia infection in humans has not been 
 determined [51].
2.2.5 Diagnosis
In outline the diagnosis of Giardia is based on the microscopic detection of 
Giardia cysts or trophozoites in a stool specimen by using wet mount, iodine 
mount, and trichrome stain method.
The string test (entro-test) may be useful for revealing Giardia trophozoites 
from duodenal sample [52].
Antigen detection assays that are available for G. intestinalis include EIAs, ELISAs, 
and direct fluorescent-antibody tests [53, 54]. For the cultivation of Giardia axenic 
media like diamond media can be used [55].
Molecular methods have higher sensitivity than conventional methods; however, 
many of them are still not commercially available [10, 52]. The use of real-time PCR 
is increasing for the detection of Giardia. Conventional single, nested, and multi-
plex PCRs have also been developed [10, 52].
2.2.6 Treatment
Metronidazole 250 mg TDS for 5 days or tinidazole 2 g once PO has been 
used as the therapy of choice. Due to the emergence of resistant isolates of 
Giardia, treatment failures and clinical relapses have been known to occur [43]. 
Alternatively, nitazoxanide 500 mg BD for 3 days can be used. Other drugs 
like furazolidone, albendazole, and paromomycin are also effective against 
giardiasis.
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2.2.7 Prevention and control
By improving food and personal hygiene and by treating asymptomatic person, 
Giardia infection can be prevented.
One vaccine (GiardiaVax) has been licensed for dogs and cats in the United 
States [56, 57]. No human vaccines are currently available [57, 58].
2.3 Cryptosporidium species
2.3.1 Introduction
It is the coccidian parasite which causes self-limiting illness in immunocompe-
tent person but can lead to severe disease in immunocompromised (AIDS) person. 
Two species of Cryptosporidium—C. parvum and C. hominis—found to be associ-
ated with human disease.
Epidemiology—The distribution of Cryptosporidium spp. is seen worldwide, 
and it mainly affects or causes severe illness in children and immunocompromised 
population. The prevalence of cryptosporidiosis in children of developing and 
developed nations was found to be 20 and 9%, respectively [59]. In adult population 
the change in prevalence of Cryptosporidium spp. was seen in the year 2000; before 
its prevalence was 3.8% in Los Angeles, and after 2000 it increased to 13% in the 
developed world [19].
Different clinical manifestations are produced by species of Cryptosporidium and 
subtype families of Cryptosporidium hominis [60].
2.3.2 Pathogenesis
Transmission—It is a waterborne disease transmitted via the fecal-oral route, by 
ingestion of contaminated salads, contaminated water supply, or recreational water, 
swimming in public pools, and it is observed that it can be transmitted from person 
to person, men who have sex with men, as well as through zoonotic infections [60]. 
Cryptosporidium spp. have a wide host range including humans, domestic pets, and 
wildlife [61]. Zoonotic transmission occurs by direct contact with infected animals 
or their feces or indirectly through the consumption of contaminated water [61, 62].
Life cycle—The environmentally resistant oocysts are produced by 
Cryptosporidium, and they sporulate when excreted in feces, and therefore, these 
oocysts are immediately infectious [63]. After ingestion of oocyst, excystation 
occurs in the intestine to liberate sporozoite which further develops into meront 
(with four merozoite). Meront form converts into macrogamete and microgametes 
that lead to zygote and finally unsporulated oocyst excreted into the feces.
Pathophysiology—In the small intestine, Cryptosporidium present inside the 
intracellular vacuoles and no characteristic changes were found on biopsy. Infection 
of Cryptosporidium is characterized by self-limiting diarrhea along with abdominal 
pain, dehydration, and malabsorption. It is an important infection in both immu-
nosuppressed (especially HIV-infected) and in transplant recipients [64] Figure 3 
(Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease; 8th 
ed. Philadelphia. Elsevier saunder’s 2015 Fig. 284–1. Life cycle of Cryptosporidium, 
p. 3174).
2.3.3 Immune dysfunction
The occurrence of cryptosporidiosis is closely related to the immune status of 
its host. It primarily affects the infants and immunocompromised individuals. In 
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recent years, several studies have highlighted the importance of innate immunity 
in cryptosporidiosis. Intestinal epithelial cells play a key role in cryptosporidi-
osis as these are the exclusive host cell for the replication of the parasite and also 
participate in the protective immune response. Epithelial cells produce chemo-
kines and attract immune cells to the infected area. They also release antimicrobial 
peptides with parasiticidal activity and induce apoptosis. Intestinal dendritic cells 
induce adaptive immunity and control Cryptosporidium parvum infection in the 
early stage [65].
Both innate and adaptive immune responses are important for controlling 
cryptosporidiosis. Innate immune responses are mediated by Toll-like receptor 
pathways, antimicrobial peptides, prostaglandins, mannose-binding lectin, cyto-
kines, and chemokines. Cell-mediated responses, particularly those involving CD4+ 
T cells and IFN-γ, play an important role. The parasite has developed several escape 
mechanisms to slow down these protective mechanisms [66].
2.3.4 Diagnosis
Routinely the diagnosis of cryptosporidiosis is done by the identification of 
oocysts in stool by microscopic examination. The staining and preservation tech-
nique enhance the sensitivity of the test. The staining technique for Cryptosporidium 
spp. includes modified Ziehl-Neelsen technique, Kinyoun’s acid-fast staining 
technique, modified Sheather’s flotation technique, and the iron-hematoxylin stain-
ing technique. Out of these staining techniques, modified Ziehl-Neelsen technique 
is widely used [67, 68].
Antigen detection assay is also used widely in the diagnosis of cryptosporidiosis; 
it is more effective in cases where oocyst numbers are low. These assays are thought 
to be more sensitive than conventional staining [69, 70]. Other tests like fluorescence 
Figure 3. 
Life cycle of Cryptosporidium. Courtesy: Ref. [112], Fig. 284–1.
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microscopy and direct fluorescent-antibody (DFA) assay have been used for the 
detection of Cryptosporidium oocysts with relatively high specificities (96–100%) 
and sensitivities (98.5–100%) [70, 71]. Molecular methods for the detection and 
differentiation of Cryptosporidium spp. include nested PCR, real-time PCR, multi-
plex real-time PCR, reverse transcription-quantitative real-time PCR, and multiplex 
tandem real-time PCR [12, 72]. More recently, an automated multiplex tandem PCR 
is used; it is based on a robotic platform and used to detect Cryptosporidium spp. 
and coinfecting diarrheal pathogens from the human fecal genomic sample [73]. 
Some new methods such as reverse line blot (RLB) hybridization, loop-mediated 
isothermal amplification method, and nucleic acid sequence-based amplification 
(NASBA) methods that amplify RNA from either RNA or DNA templates are also 
used for the diagnosis of Cryptosporidium spp. [72, 74]. Another new technique for 
the detection of Cryptosporidium spp. includes next-generation sequencing, DNA 
microarray, etc. which are also available [70] (Figure 4).
2.3.5 Treatment
In immunocompetent persons, cryptosporidiosis is usually self-limiting, 
requiring little or no treatment, but in immunosuppressed person, treatment is 
required [75]. Nitazoxanide 500 mg BD for 3 days has proven to be effective against 
cryptosporidiosis. In patients with dehydration, rehydration fluids and nutritional 
management may be required.
Nitazoxanide is the only licensed drug for the treatment of cryptosporidiosis, 
and it is given only in persons after the first year of life and with healthy immune 
systems. Recently trials are going on clofazimine, a drug used for leprosy, to know 
its effectiveness against Cryptosporidium spp. [76].
2.3.6 Prevention and control
Prevention can be done by avoiding exposure to infectious oocyst in human or 
animal feces, proper hand washing, and improved personal hygiene. No vaccines 
are available for use against Cryptosporidium spp. [76].
Figure 4. 
Oocyst of Cryptosporidium on modified ZN stain.
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This is a coccidian parasite, and the only species of this genus found in humans 
is Cyclospora cayetanensis. Similar to Cryptosporidium, Cyclospora is also associated 
with severe illness in immunocompromised patients in comparison to immunocom-
petent patients.
Epidemiology—Human cyclosporiasis is distributed worldwide, and cases are 
reported both from tropical and subtropical areas of the world. According to a 
study from China, the prevalence of Cyclospora spp. from 2007 to 2009 was 0.70%, 
whereas in the United Kingdom at the same time, the prevalence was 0.07% [77].
2.4.2 Pathogenesis
Transmission—An important feature of the C. cayetanensis is that the direct 
fecal-oral transmission from fresh stool is not seen because the oocysts require days 
to weeks outside the host to sporulate and become infectious.
Life cycle and pathophysiology—Similar to cryptosporidium spp.
Clinical feature—Infection due to Cyclospora manifest as persistent diarrhea, 
fever, bloating, flatulence, abdominal cramps, constipation, and fatigue, weight 
loss, etc.
Immune dysfunction—similar to Cryptosporidium spp.
2.4.3 Diagnosis
Routinely the diagnosis of Cyclospora is done by using microscopic methods. 
Cyclospora oocyst produces autofluorescence (white-blue) under an epifluorescence 
microscope [78, 79]. By demonstration of Cyclospora oocysts, autofluorescence and 
staining characteristics diagnosis can be made. Oocysts appear as acid-fast round 
or ovoid very small (8–10 μm) structures. The diameter measurement of oocyst is 
important to differentiate it from smaller Cryptosporidium oocysts, which measure 
4–6 μm in size. The procedures used to diagnose Cyclospora includes concentration 
by the formalin-ethyl acetate technique followed by either (i) UV epifluorescence 
and bright-field microscopy, (ii) examination of a modified acid-fast-stained stool 
slide, or (iii) examination using a modified safranin-based technique [80].
Molecular techniques have been developed like various PCR tools that target the 
internal transcribed spacer region, which use primers for the 18S rRNA gene [79]. 
These tools include conventional PCR, reverse transcriptase PCR in combination 
with agarose gel electrophoresis, and nested PCR [79]. Cyclospora is included in the 
BioFire FilmArray systems GIT panel; hence, syndromic diagnosis can be made.
2.4.4 Treatment
Laboratory diagnosis is important as the treatment of Cyclospora is different 
from the other protozoa of similar presentation. Trimethoprim-sulfamethoxazole 
(also known as co-trimoxazole) 160/800 mg BD for 7–10 days is the drug of choice 
for cyclosporiasis.
2.4.5 Prevention and control
No vaccine is available till now against Cyclospora; by avoiding contaminated 
food and water it can be prevented.
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2.5 Cystoisospora belli (formerly Isospora belli)
2.5.1 Introduction
Cystoisospora belli is responsible for intestinal disease in several mammalian 
hosts. It is also a coccidian parasite similar to Cryptosporidium and Cyclospora. It is 
also found to be associated with more severe illness in immunocompromised host.
2.5.2 Epidemiology
Very little is known about the epidemiology and prevalence of Cystoisospora belli. 
The worldwide reported prevalence of Cystoisospora belli was 2.5–26.1%, and it is 
mostly seen in HIV-positive individuals [18].
2.5.3 Pathogenesis
Transmission—Infection occurs via the ingestion of mature sporulated oocysts 
present in contaminated food or water.
Life cycle and pathophysiology—Similar to Cryptosporidium spp.
Clinical feature—Infection is manifested as watery diarrhea, abdominal cramps, 
anorexia, and weight loss, and it is almost indistinguishable from cryptosporidi-
osis. It is more common in AIDS patients and causes traveler’s diarrhea in travelers 
to developing countries. In HIV-infected patients, infection of Cystoisospora belli 
may lead to chronic diarrhea, acalculous cholecystitis cholangiopathy, and extrain-
testinal infection [81]. Other Cystoisospora species causes of diarrhea in domestic 
animals, like Cystoisospora suis, lead to severe diarrheal illness in pigs [82].
Immune dysfunction—Similar to cryptosporidium spp.
Diagnosis is made by demonstration of oocyst by direct microscopic examina-
tion of the feces, with acid-fast staining or fluorescent staining with auramine and 
rhodamine. Oocysts of Cystoisospora belli are large (20–23 μm × 10–19 μm) and 
ellipsoidal in shape in comparison to oocyst of Cryptosporidium which is round 
and 4–6 μm in diameter.
Autofluorescence can be seen, but this property is not consistent in Cystoisospora.
In molecular techniques PCRs using SSU rRNA primer have shown excellent 
sensitivity and specificity for the detection of C. belli in fecal samples. But these 
tests are not commercially available [83, 84] (Figure 5).
Treatment is done by giving oral co-trimoxazole 160/800 mg BD for 10 days 
and in case of HIV-infected patients three times daily for 3 weeks. Other drugs like 
ciprofloxacin, pyrimethamine, and folinic acid are good alternative.
2.5.4 Prevention and control
To date no vaccines are available for Cystoisospora belli; however, trials are going 
on to identify the suitable candidate of parasite for vaccine preparation [85]. Hence, 
prevention can be done by avoiding contaminated food and water consumption.
2.6 Dientamoeba fragilis
2.6.1 Introduction
It was initially considered as amoeba but recently classified under ameboflagel-
late as it has internal flagellum. It mostly involves the lumen of the cecum and upper 
colon of the human intestine.
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Epidemiology—The reported prevalence of Dientamoeba fragilis in the year of 
2015 was around 1–70% in developed settings [86]. It varies globally as in United 
States and Australia; the reported prevalence is 5%, and in Netherland it was 
around 8% [87].
2.6.2 Pathogenesis
Many debates are there for the pathogenicity of D. fragilis [88, 89]. Previously it 
was thought that in D. fragilis, cyst stage has not been found [89], but recently both 
the cyst and precyst stage have been identified [90]. The nuclear chromatin of tro-
phozoite of D. fragilis is fragmented into 3–5 granules; hence, it is known as fragilis. 
Although the mode of transmission remains unknown, previously it was thought 
that infection occurs via the pinworm vector because of its high rates of coinfection 
with Enterobius vermicularis [91]. But according to recent studies, it is found that 
transmission occurs directly via the fecal-oral route [89].
Clinical symptoms of Dientamoeba fragilis infection include abdominal pain, 
persistent diarrhea, loss of appetite, weight loss, and flatulence. Symptoms of D. 
fragilis are similar to those of irritable bowel syndrome (IBS); hence, it should be 
considered in the differential diagnosis of IBS [92].
2.6.3 Immune dysfunction
Dientamoeba fragilis is often described as “neglected parasite” [93]. Recently, 
several studies have occurred on the life cycle and molecular biology of the organ-
ism, but the knowledge on immune response against the pathogen is lacking. 
Because of the close relativity of Dientamoeba fragilis to histomonads, the immu-
nological research on H. meleagridis can give an indication to the immunological 
responsiveness of host against D. fragilis [94].
2.6.4 Diagnosis
It is based on the microscopic detection of trophozoites in fresh or fixed stool 
specimens. The trophozoites degrade soon after passing in the stool; hence, the 
examination should be done immediately. Modified iron-hematoxylin or trichrome 
staining of fixed smears is considered the gold standard for the diagnosis of  
Figure 5. 
Oocyst of Cystoisospora in modified ZN stain.
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D. fragilis infection [95]. But in comparison to molecular methods, this method is 
time-consuming and relatively insensitive [96]. The demonstration of the charac-
teristic nuclear structure is needed for the definitive diagnosis of D. fragilis which 
cannot be seen in unstained fecal material. Hence, fixation and staining are neces-
sary for definitive diagnosis of D. fragilis [96].
Antigen detection by rapid fecal immunoassays like enzyme immunoassays, 
fluorescent antibody, and rapid cartridge formats is previously under trial, but 
now enzyme immunoassay and immunofluorescence tests are available for antigen 
detection [90].
Antibody detection can be done by using an indirect immunofluorescence 
method [90].
For the cultivation of D. fragilis, no axenic cultures exist, and it will grow well 
in xenic cultures. For growth of D. fragilis, Loeffler’s slope medium and modified 
Earle’s balanced salt solution media are used [90].
Recently, the more advanced tests based on various conventional and real-time 
PCRs are used to detect the small subunit (SSU) rRNA gene of D. fragilis. These 
tests are more rapid, sensitive, and specific for the diagnosis in fresh stools [96]. 
Molecular methods are more sensitive than microscopy and staining but still not 
commercially available. Dientamoeba fragilis is not included in the gastrointestinal 
panel of BioFire FilmArray system [90].
2.6.5 Treatment
For the treatment of D. fragilis paromomycin, secnidazole, iodoquinol, tetra-
cycline, ornidazole, and metronidazole have been used successfully. The treat-
ment is recommended both in symptomatic patients and asymptomatic family 
members to prevent reinfection. There are few studies which show emergence 
of resistance or treatment failures of metronidazole therapy; it suggests that the 
combination therapy should be used for these protozoa [97]. For the complete 
eradication of the parasite and in resolution of symptoms, combination therapy is 
effective [97].
2.6.6 Prevention and control
By improving personal hygiene, Dientamoeba infection can be prevented. No 
vaccines available yet for Dientamoeba fragilis.
2.7 Blastocystis species
2.7.1 Introduction
Blastocystis spp. are commonly isolated from stools of humans and animals [13]. 
There are numerous subtypes of Blastocystis spp., but it is unclear whether any of 
these subtypes are specific to humans disease. It was found that Blastocystis sp. 
subtype 3 is most commonly associated with illness in human [13, 98]. It appears in 
various morphological forms like vacuolar, granular, amoeboid, and cyst forms, and 
less frequently avacuolar and multivacuolar cells and cells containing filament-like 
inclusions [99, 100].
Epidemiology—The prevalence of Blastocystis spp. in developed countries is 
0.5–23% and in developing countries 22–100%. The prevalence varies in different 
geographical are according to the socioeconomic status of that area [101].
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2.7.2 Pathogenesis
Transmission is usually taken place via the fecal-oral route through the con-
sumption of cyst. These cysts may be waterborne or foodborne. There are many 
zoonotic subtypes of Blastocystis spp. which supports the increased potential for 
zoonotic transmission [102].
Life cycle—Infection is acquired through the consumption of cyst, and it con-
verts to vacuolar, granular, and amoeboid form in human intestine. Cyst form is 
excreted in the feces and contaminates the food and water ingested by other animals.
Clinical features of Blastocystis spp. infection include mostly asymptomatic 
or nausea, anorexia, abdominal pain, flatulence, and acute or chronic diarrhea. 
Blastocystis spp. have been found to be the most common enteric organisms isolated 
from diarrheal patients but have been reported as noninfectious pathogens or a 
member of normal gut microbiota [103].
2.7.3 Immune dysfunction
According to a study, the incubation of Blastocystis sp. ST1 cells or culture filtrates 
induces the production of proinflammatory cytokines interleukin (IL)-8 and 
granulocyte-macrophage colony-stimulating factor. It suggests that the parasite was 
able to modulate the host immune response. Blastocystis sp. releases cysteine prote-
ases, which induce human colonic epithelial cells (HT84) for the production of IL-8. 
Cysteine proteases of Blastocystis sp. are involved in parasite survival in vivo and rep-
resent virulence factors. Blastocystis sp. also secretes protease, which is able to cleave 
human secretory immunoglobulin A. Apart from proteases, hydrolases and protease 
inhibitors were predicted to be secreted by Blastocystis sp. which participates in the 
blastocystosis physiopathology and its mechanisms for immune evasion [104].
2.7.4 Diagnosis
The diagnosis of infection with Blastocystis spp. is done by using wet mount 
smears, iodine staining, trichrome staining, or iron-hematoxylin staining and 
detecting the vacuolar, granular, amoebic, or cystic form in stool samples [13, 100]. 
Trichrome staining of fecal smears or xenic in vitro culture systems has better sensi-
tivity [98]. Subtype 7 which is a slower-growing subtype of Blastocystis spp. may be 
missed with this procedure [98].
For antibody detection in serum ELISA and immunofluorescent assay are 
also available. ELISA for the antigen detection in the stool is also introduced 
recently [105].
In molecular techniques, PCR using the SSU rRNA gene is being used increas-
ingly for the detection of Blastocystis spp. with increased sensitivity, and it is 
more commonly used method nowadays [13]. Based on SSU rRNA 17, subtypes of 
Blastocystis spp. were identified out of which ST3 is the commonest worldwide [106] 
(Figure 6).
2.7.5 Treatment
Drugs used for the treatment of pathogenic Blastocystis spp. include metroni-
dazole, co-trimoxazole, nitazoxanide, and a combination of paromomycin and 
metronidazole. Among these metronidazole is the drug of choice, although failures 
of this drug in eradicating the organism are common [107].
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2.7.6 Prevention and control
Prevention can be done by avoiding the contaminated food and water consump-
tion; no vaccines are available for Blastocystis spp. till now.
2.8 Balantidium coli
2.8.1 Introduction
Balantidium coli is the largest protozoan that infects humans. It belongs to the 
ciliate group. The whole body of the organism is covered with a row of cilia which is 
responsible for the rotary motility of B. coli (Figure 7).
2.8.2 Epidemiology
It mostly occurred in tropical and subtropical areas of developing countries. The 
estimated prevalence of B. coli worldwide is 1% as the human infection with this 
protozoa is rare [108].
2.8.3 Pathogenesis
Transmission—Pigs are the natural host for B. coli. Human acquires infec-
tion by ingestion of cysts present in water and undercooked food (fecal-oral 
route).
Life cycle—After ingestion of cyst, it converts into trophozoite in the large intes-
tine of human. Both cyst and trophozoite are excreted into the feces, but in external 
environment, trophozoite disintegrates and cyst will survive. It contaminates the 
water and food, and the life cycle continues.
Clinical feature—Infections of B. coli are mostly asymptomatic, but in symp-
tomatic patients, mild diarrhea and abdominal discomfort have been reported. 
In a few patients fulminating acute balantidiasis, with intestinal perforation, can 
Figure 6. 
Cysts of Blastocystis hominis on wet mount. Courtesy: Ref. [113], Fig. 285–5.
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develop which has a case fatality rate of about 30%. Fulminating dysentery, resem-
bling amoebic dysentery, can also occur in B. coli infection [108].
2.8.4 Immune dysfunction
Immune response in B. coli is poorly understood due to the lack of studies available. 
It was found that infection of B. coli is more severe in immunocompromised patients.
2.8.5 Diagnosis
B. coli is diagnosed by its large size cysts (50–70 μm) and trophozoite 
(30–200 μm × 40–70 μm) and rotatory motility which is demonstrated by wet 
mount slide preparations. Trophozoites of B. coli are visible even with hand lens 
and, sometimes with the naked eye, in freshly collected diarrheic stools as well as 
in bronchoalveolar wash fluid [108]. Collection of stool samples should be done for 
several days because the excretion of parasites can be erratic [108].
Balantidium coli can be cultivated on Boeck and Drbohlav egg serum media and 
Balamuth media. It can also be cultivated on Pavlova xenic culture media, and the 
growth of trophozoites can be obtained within 72 h on this media [109].
2.8.6 Treatment
B. coli is treated with tetracycline or metronidazole:
• Tetracycline—500 mg qid for 10 days
• Metronidazole 750 mg tds for 5–7 days
2.8.7 Prevention and control
By avoiding contamination of food and water with pig and human feces and by 
treating the carrier shedding the cyst, the infection can be prevented. No vaccines 
are available till now for Balantidium coli infection.
Figure 7. 
Trophozoite of B. coli demonstrating cilia on the surface. Courtesy: Ref. [114], Fig. 285–4.
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3. Conclusion
Enteric protozoa are responsible for severe morbidity and mortality in humans. 
Protozoal infections contribute to the high burden of infectious diseases. Despite 
recent advances in the epidemiology, diagnostic tool, molecular biology, and 
treatment of protozoan illnesses, gaps in knowledge still exist; hence, protozoal 
infections require further research. Both humoral and cellular immunities play an 
important role in the protection of host against enteric protozoal infection. Protozoa 
have some virulence factor or mechanism to evade the immune system of the 
host, for the production of disease. An already dysfunctional host immune system 
(immunocompromised conditions) helps the protozoa to cause easy and more 
serious disease. Among these enteric protozoal infection Entamoeba histolytica, 
Giardia intestinalis, Cryptosporidium, Cyclospora, Cystoisospora belli, Dientamoeba 
fragilis, Blastocystis, and Balantidium coli are common. In the recent years, increas-
ing trends of Entamoeba histolytica, Giardia intestinalis, and Cryptosporidium is seen 
both in developing and developed countries. Blastocystis is an emerging infection to 
humans. Mostly enteric protozoal infections are acquired through fecal-oral route 
and present with abdominal pain and fever mainly. Some of them can lead to ane-
mia and malabsorption syndrome. If not diagnosed or treated timely, enteric pro-
tozoal infection can be fatal. Diagnosis for most of them is based on microscopy,but 
recently many molecular methods are available to diagnose them. By using multi-
plex PCR, BioFire Gastrointestinal panel, common diarrheal illness-causing organ-
isms can be identified in a shorter time span. ELISA and immunofluorescent assay 
are also available for some of them, e.g., Blastocystis spp. and Dientamoeba fragilis. 
For the treatment of protozoal infection, drugs like metronidazole, paromomycin, 
diloxanide furoate, nitazoxanide, cotrimoxazole, etc. are used. The infection can be 
prevented by good personal hygiene and by avoiding food and water contamination. 
Till date, no vaccines are available for human use against these protozoal infections.
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